Tag: Ofatumumab

Many individuals undergoing treatment for multiple sclerosis with Kesimpta experience common side effects such as headaches or injection-related discomfort, particularly following the initial doses. To manage these symptoms, a frequent question arises: **Can you take ibuprofen while on Kesimpta?**

According to the U.S. Food and Drug Administration (FDA) prescribing information, Kesimpta is contraindicated in patients with an active Hepatitis B virus (HBV) infection or a history of a life-threatening injection-related or hypersensitivity reaction to the drug. Understanding **what are the contraindications for Kesimpta** is crucial for patient safety and effective treatment planning.

Many people carry the John Cunningham (JC) virus, which, in those with weakened immune systems, can lead to a rare but serious brain infection called Progressive Multifocal Leukoencephalopathy (PML). For individuals with multiple sclerosis (MS) who test positive for the virus, a key question is whether they can take Kesimpta if they are JCV positive.

In clinical trials, a significant number of patients reported systemic injection-related reactions, most commonly within 24 hours of the first Kesimpta dose. This initial experience, alongside long-term side effects like increased vulnerability to infections, helps answer the crucial question: how does Kesimpta make you feel?

Over 1 million Americans are living with multiple sclerosis (MS), a chronic, unpredictable disease that affects the central nervous system. In the landscape of disease-modifying therapies (DMTs), B-cell targeting agents like Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) have become cornerstones of treatment for relapsing forms of MS. Choosing which is better, Kesimpta or Ocrevus, is a complex decision that involves weighing several factors, from the method of administration to subtle differences in clinical outcomes.

The annual list price for Kesimpta can exceed $100,000, with a single monthly dose costing over $9,000. However, the out-of-pocket expense for patients managing multiple sclerosis is rarely this high, as the final cost depends heavily on insurance and available financial assistance programs. This article explores the factors determining how much Kesimpta costs and how to access support.

Since its initial U.S. approval in 1997, rituximab has revolutionized the treatment of B-cell malignancies and autoimmune diseases [1.5.1, 1.12.3]. For patients and clinicians asking 'What is an alternative to rituximab?', a new generation of advanced therapies offers promising options with improved efficacy and novel mechanisms.